Efficacy and Safety of Radiotherapy Combined with Liposomal Irinotecan, Camrelizumab, and Anti-angiogenic Therapy in Advanced Bone and Soft Tissue Sarcoma: A Retrospective Subgroup Analysis of CAP Study
10.3971/j.issn.1000-8578.2026.25.0718
- VernacularTitle:放疗联合脂质体伊立替康、卡瑞利珠单抗及抗血管生成治疗对晚期骨与软组织肉瘤的疗效与安全性：CAP研究的亚组分析
- Author:
Wanru WANG
1
;
Yuchen GE
2
;
Xiaolu WANG
2
;
Juan LIU
2
;
Yue CAO
3
;
Baorui LIU
2
;
Jie SHEN
2
;
Rutian LI
1
Author Information
1. Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China;Cancer Center, Drum Tower Hospital Affiliated to Nanjing University School of Medicine and Institute of Clinical Oncology, Nanjing University, Nanjing 210008, China.
2. Cancer Center, Drum Tower Hospital Affiliated to Nanjing University School of Medicine and Institute of Clinical Oncology, Nanjing University, Nanjing 210008, China.
3. Nanjing University School of Medicine, Nanjing 210008, China.
- Publication Type:CLINICALRESEARCH
- Keywords:
Bone and soft tissue sarcoma;
Radiotherapy;
Liposomal irinotecan;
Camrelizumab;
Anti-angiogenic therapy
- From:
Cancer Research on Prevention and Treatment
2026;53(7):542-548
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of a combination therapy regimen comprising stereotactic body radiation therapy (SBRT) combined with liposomal irinotecan, camrelizumab, and anti-angiogenic therapy (CAP) in patients with advanced bone and soft tissue sarcomas. Methods This study is a prospective subgroup analysis of the multicenter, open-label, single-arm phase Ⅱ CAP trial (NCT04569916), which enrolled 60 patients with advanced solid tumors who had progressed after standard therapy between November 2020 and February 2023, including 11 patients with advanced bone and soft tissue sarcomas. All patients received sequential liposomal irinotecan within 48 hours after stereotactic body radiotherapy (SBRT), followed by maintenance therapy with camrelizumab and an anti-angiogenic agent until disease progression or intolerable toxicity. The primary efficacy endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results In the bone and soft tissue sarcoma subgroup (n=11), three patients achieved partial response (PR), five had stable disease (SD), and three experienced disease progression (PD). ORR was 27.3%, and DCR was 72.7%. mPFS was 5.8 months (95%CI: 2.2-10.3), and mOS not reached. Regarding safety, adverse reactions primarily included bone marrow suppression, fatigue, and gastrointestinal reactions, indicating overall manageable toxicity. Conclusion As a subgroup analysis of the CAP study, this research suggests that radiotherapy combined with liposomal irinotecan, camrelizumab, and anti-angiogenic therapy demonstrates certain efficacy in advanced bone and soft tissue sarcomas that have failed multiple lines of treatment, with overall manageable adverse reactions. Future studies should expand the sample size.
